Harmony Biosciences

US · HRMY #2681 by market cap Listed 2020

39.34 -0.02 -0.05%

Live - 5344 symbols - heartbeat 69s ago · 2026-10-08 03:12

After-hours 39.25 -0.23%

Overnight 38.91 -1.09%

Market cap: 2.29B
P/E (TTM): 12.73
P/B: 2.29
EPS: 2.71
Div yield: 0.00%
52W pos: 77%

Reader sentiment Are you bullish or bearish on HRMY?

Anonymous reader poll. Unscientific, not investment advice.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Founded: 2017
CEO: Dr. Jeffrey M. Dayno, M.D.
Employees: 293
Headquarters: Plymouth Meeting, Pennsylvania, United States of America
Fiscal year end: 12-31
Website: harmonybiosciences.com

Company profile

Exchange: US
Symbol: HRMY
Market-cap rank: #2681
Listing date: 2020-08-19
Market cap: 2.29B
Float cap: 2.05B
Shares out: 58.24M
Float shares: 52.10M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 03:12:05 · For reference only, not investment advice and not tailored to your situation.